CSBio CSBio

X
[{"orgOrder":0,"company":"Trigr","sponsor":"Elpiscience","pharmaFlowCategory":"D","amount":"$117.0 million","upfrontCash":"$7.0 million","newsHeadline":"TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"EUROPE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Trigr"},{"orgOrder":0,"company":"Trigr","sponsor":"Compass Therapeutics","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"EUROPE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Trigr"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Compass Therapeutics obtains global rights to TR009, a novel bispecific antibody and inhibitor of the notch pathway targeting DLL4 and VEGF-A.

            Lead Product(s): CTX-009

            Therapeutic Area: Oncology Product Name: TR009

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Compass Therapeutics

            Deal Size: $14.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition May 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territory.

            Lead Product(s): Asciminib

            Therapeutic Area: Oncology Product Name: ABL001

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Elpiscience

            Deal Size: $117.0 million Upfront Cash: $7.0 million

            Deal Type: Collaboration January 20, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY